Oral formulations for counteracting effects of aging

1. An oral formulation, comprising pomegranate extract, Panax ginseng extract, and Cordyceps sinensis ( C. sinensis ), each present in an amount effective to counteract effects of aging in a subject when administered to the subject, wherein the oral formulation is more effective to counteract the effects in the subject to a greater degree than any one of pomegranate extract, Panax ginseng extract, and C. sinensis.

2. The oral formulation of claim 1 , further comprising at least one strain selected from Paecilomyces hepialis ( P. hepialis ) and Hirsutella sinensis ( H. sinensis ).

3. The oral formulation of claim 1 , wherein the Panax ginseng extract includes ginsenoside Rb1 and ginsenoside Rg1 at a ratio of about 3:1 to about 5:1.

4. The oral formulation of claim 1 , wherein the pomegranate extract includes at least 80 wt % polyphenols.

5. The oral formulation of claim 1 , further comprising at least one additive selected from the group consisting of a gum, an anti-caking agent, lecithin, microcrystalline cellulose, silica gel, and flavoring.

6. The oral formulation of claim 1 , further comprising at least one additional active agent selected from the group consisting of: Schizandra berry extract, whole grape extract, CoenzymeQ 10 , Rhodiola rosacea extract, Tart cherry extract, and L-carnitine tartrate.

7. The oral formulation of claim 1 , present in a dosage form selected from the group consisting of: capsule, tablet, powder, beverage, wafer, confectionary, chewable, gel, paste, elixir, syrup, drops, and lozenge.

8. The oral formulation of claim 1 , in a dosage form containing about 140 mg to about 200 mg pomegranate extract, from about 70 mg to about 130 mg Panax ginseng extract, and from about 1800 mg to about 2200 mg C. sinensis.

9. The oral formulation of claim 1 , wherein the effect is a decline in energy metabolism.

10. The oral formulation of claim 1 , wherein the effect is a decline in sexual performance.

11. The oral formulation of claim 1 , wherein the effect includes age-related changes in gene expression.

12. The oral formulation of claim 11 , wherein the gene expression is for a biomarker of aging.

13. The oral formulation of claim 11 , wherein the gene expression occurs in muscle tissue.

14. The oral formulation of claim 11 , wherein the gene expression occurs in brain tissue.

15. The oral formulation of claim 1 , wherein the formulation counteracts the effect in the subject to an equivalent or greater degree than caloric restriction in the same subject.

16. An oral formulation comprising: pomegranate extract at about 0.09 wt % to about 80.32 wt %; Cordyceps sinensis ( C. sinensis ) at about 13.46 wt % to about 99.67 wt %; and Panax ginseng extract at about 0.19 wt % to about 67.72 wt %.

17. The oral formulation of claim 16 , wherein pomegranate extract is present at from about 6.5 wt % to about 8.0 wt %, Panax ginseng extract is present at from about 3.5 wt % to about 5.0 wt %, and C. sinensis is present at from about 83.0 wt % to about 89 wt %.

18. The oral formulation of claim 16 , wherein the oral formulation counteracts an effect of aging in a subject when administered to the subject.

19. The oral formulation of claim 18 , wherein the effect is a decline in energy metabolism.

20. The oral formulation of claim 18 , wherein the effect is a decline in sexual performance.

21. The oral formulation of claim 18 , wherein the effect includes age-related changes in gene expression.

22. The oral formulation of claim 21 , wherein the gene expression is for a biomarker of aging.

23. The oral formulation of claim 21 , wherein the gene expression occurs in muscle tissue.

24. The oral formulation of claim 21 , wherein the gene expression occurs in brain tissue.

25. The oral formulation of claim 18 , wherein the formulation counteracts the effect in the subject to a similar or greater degree than caloric restriction in the same subject.

26. The oral formulation of claim 18 , wherein an amount of the oral formulation counteracts the effect in the subject to a greater degree than an equal amount of any one of pomegranate extract, Panax ginseng extract, and C. sinensis.

27. The oral formulation of claim 16 , further comprising at least one strain selected from Paecilomyces hepialis ( P. hepialis ) and Hirsutella sinensis ( H. sinensis ).

28. The oral formulation of claim 16 , wherein the Panax ginseng extract includes ginsenoside Rb1 and ginsenoside Rg1 at a ratio of about 3:1 to about 5:1.

29. The oral formulation of claim 16 , wherein the pomegranate extract includes at least 80 wt % polyphenols.

30. The oral formulation of claim 16 , further comprising at least one additive selected from the group consisting of a gum, an anti-caking agent, lecithin, microcrystalline cellulose, silica gel, and flavoring.

31. The oral formulation of claim 16 , further comprising at least one additional active agent selected from the group consisting of: Schizandra berry extract, whole grape extract, CoenzymeQ 10 , Rhodiola rosacea extract, Tart cherry extract, and L-carnitine tartrate.

32. The oral formulation of claim 16 , present in a dosage form selected from the group consisting of: capsule, tablet, powder, beverage, wafer, confectionary, chewable, gel, paste, elixir, syrup, drops, and lozenge.

33. A method of counteracting an effect of aging in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 1 .

34. The method of claim 33 , wherein the therapeutically effective amount delivers to the subject a daily dose comprising about 0.15 mg/kg to about 30.0 mg/kg of pomegranate extract, about 0.35 mg/kg to about 15 mg/kg of Panax ginseng extract, and about 15.0 mg/kg to about 150.0 mg/kg of C. sinensis.

35. The method of claim 33 , wherein the oral formulation includes pomegranate extract at about 0.09 wt % to about 80.32 wt %; C. sinensis at about 13.46 wt % to about 99.67 wt %; and Panax ginseng extract at about 0.19 wt % to about 67.72 wt %.

36. The method of claim 33 , wherein the subject is human.

37. The method of claim 33 , wherein the composition further comprises at least one strain selected from Paecilomyces hepialis ( P. hepialis ) and Hirsutella sinensis ( H. sinensis ).

38. The method of claim 33 , wherein the Panax ginseng extract includes ginsenoside Rb1 and ginsenoside Rg1 at a ratio of about 3:1 to about 5:1.

39. The method of claim 33 , wherein the pomegranate extract includes at least 80 wt % polyphenols.

40. The method of claim 33 , further comprising at least one additive selected from the group consisting of a gum, an anti-caking agent, lecithin, microcrystalline cellulose, silica gel, and flavoring.

41. The method of claim 33 , further comprising at least one additional active agent selected from the group consisting of: Schizandra berry extract, whole grape extract, CoenzymeQ10, Rhodiola rosacea extract, Tart cherry extract, and L-carnitine tartrate.

42. The method of claim 33 , wherein the oral formulation is present in a dosage form selected from the group consisting of: capsule, tablet, powder, beverage, wafer, confectionary, chewable, gel, paste, elixir, syrup, drops, and lozenge.

43. The method of claim 33 , wherein the effect is a decline in energy metabolism.

44. The method of claim 33 , wherein the effect is a decline in sexual performance.

45. The method of claim 33 , wherein the effect includes age-related changes in gene expression.

46. The method of claim 45 , wherein the gene expression is for a biomarker of aging.

47. The method of claim 45 , wherein the gene expression occurs in muscle tissue.

48. The method of claim 45 , wherein the gene expression occurs in brain tissue.

49. The method of claim 45 , wherein the formulation counteracts the effect in the subject to a similar or greater degree than caloric restriction in the same subject.

50. A method of counteracting changes in gene expression in a tissue, comprising treating the tissue with a therapeutically effective amount of the composition of claim 1 .

51. The method of claim 50 , wherein the changes in gene expression are a function of the age of a subject from which the tissue is obtained.

52. The method of claim 50 , wherein the composition further comprises at least one strain selected from Paecilomyces hepialis ( P. hepialis ) and Hirsutella sinensis ( H. sinensis ).

53. The method of claim 50 , wherein the pomegranate extract includes at least 80 wt % polyphenols.

54. The method of claim 50 , wherein the Panax ginseng extract includes ginsenoside Rb1 and ginsenoside Rg1 at a ratio of about 3:1 to about 5:1.

55. The method of claim 50 , wherein the oral formulation includes pomegranate extract at about 0.09 wt % to about 80.32 wt %; C. sinensis at about 13.46 wt % to about 99.67 wt %; and Panax ginseng extract at about 0.19 wt % to about 67.72 wt %.